Replies to post #270855 on Amarin Corp Plc (AMRN)

[Whalatane]

N7 /Rose /Montana ..clock is ticking re EU exclusivity
Anyone care to calculate the cost of NOT having Vascepa on the EU market as soon as the EMA approves the R-IT indication for the EU market ..

Ask HDG ...who I nominate to run AMRN GIA EU operations IF they ever try to

Has anyone on this board EVER lived in the EU ( besides myself , Jas , maybe a few others and obviously HDG ) ...if so please identify yourself so that you can be recognized at least as being credibly informed ...whether your view is +ve or -ve on the idea of GIA in the EU

Kiwi

[NickHous]

I say we have clarity on US market. As it stands right now, go with assumption we have "XX" number of months of being the only provider of Vascepa until generics are up and running. Then we blow out our own "generic Vascepa". AMRN should be able as a "worst case scenario" put a NPV on that scenario for BP interest. Put a CVR value on if we win appeal. Put a NPV on EU and ROW. Then begin/continue the negotiations. If they are not in negotiations with a BP right now, then we are in trouble. GIA in EU is just idle chatter due to inability to disclose that negotiations are occurring. Just starting to entertain the idea that JT would be gone unless some type of negotiations were occurring. If BOD really wanted GIA, then why keep current CEO after patent ruling. I mean we have heard nothing from BOD after all this. His "wholistic" approach is occurring, sell it all. All just my opinion.